Mifepristone
It is used for the termination of early pregnancy, as well as for other medical applications such as the treatment of Cushing's syndrome.
Mifepristone binds to the progesterone receptor and blocks the action of the natural hormone progesterone, resulting in the disruption of early pregnancy development.
Expeience the power of PubCompare.ai today to optimize your Mifepristone research and identify the best protocols and products for enhanced reproducibility and accuracy.
Most cited protocols related to «Mifepristone»
for over-expression (Table
Act-GS-255A contain multiple copies of a P element construct in which
expression of the Geneswitch cDNA is under the control of the tissue-general Actin5C promoter [16 (link)]. The UAS-ultraGFP strain contain multiple copies of a UAS-eGFP
construct, and its construction and characterization have been recently
described [18 ]. The Geneswitch system drivers Elav-GS, MHC-GS, S1-32
and S1-106 were generously provided by T. Osterwalder and R. Davis
[19 (link),20 (link)].
GeneSwitch virgins were used in the crosses with males of other lines, with the
exception of strains in which the target transgene for over-expression was on
the X chromosome. Life span assays consisted of ~25 flies per vial, and a total
5 vials for each cohort. For survival assays performed at 25oC,
flies were transferred to new vials ever other day. For survival assays
preformed at 29oC flies were transferred to new vials every other
day during the first 30-40 days, and then every day for the remainder of the
life span. RU486 (Mifepristone, Sigma) was dissolved in ethanol (100%) to make
a stock solution of 3.2mg/ml. For adult feeding, 50ul RU486 stock solution was
added to the surface of each vial to produce a final concentration of
~160ug/ml; 50ul ethanol was added to the control vials. For larval feeding,
0.5ml of 3.2mg/ml RU486 stock solution (or the indicated diluted concentration)
was added to the surface of each bottle to produce a final concentration of
~160ug/ml (or indicated diluted concentration); 0.5ml ethanol was added to
control bottles.
flies were cultured in vials in the presence and absence of drug for two weeks
prior to dissection. Adult male and female flies, head in half, body in half,
midgut and hindgut, ovary and testes, were photographed. Larvae at 1st instar, 2nd instar and 3rd instar, as well as 3rd instar dissected tissues (brain, midgut and hindgut, salivary gland, imaginal
discs, and fat body) were also photographed. The Leica MZ FLIII fluorescence
stereomicroscope together with the SPOT software were used for photographs: The
GFP pictures were taken under the fluorescent light with exposure time 4 sec
and a gain of 2.
median, percent change in mean, percent change in median, and log rank p value were calculated using R 2.6.2 [58 ]. Analysis of mortality rate was
performed with the WinModest statistical package [59 ]. In the
Gompertz-Makeham model, the increaseof mortality (μx )
with age (x) is expressed as: μx= aebx+c,
where the constant a is the initial mortalityrate, b is the rate of exponential increase in mortality, and c is the
age-independent mortality. The age specific mortality rate (μx)
was calculated using WinModest by binning the days over which deaths
were counted (since fly deaths were recorded every other day) such that μx = (-ln(Nx + δx / Nx )) / δx(or Px = Nx + δx / Nx and μx = -1/δx ln(Px )), where Nxis the number of flies alive at day x and δx is the bin size [2 (link)].
Parameters (a, b, c) were also calculated based on a likelihood ratio
test. The full model (aebx+c) was plotted, and the
Gompertz-only component (aebx) was used to build the
decomposed survival curves, using μx: μx= aebx, Px= e-μx.
For the decomposed survival curves, any value below 0.5% survival was
considered to be the final data point.
Most recents protocols related to «Mifepristone»
Example 4
Composition H was manufactured according to the following procedure:
- a) Specified amount of purified water was taken in a suitable container and specified quantity of docusate sodium was added and stirred continuously to obtain a solution.
- b) Sodium lauryl sulphate was added to the step (a) solution and stirred continuously to obtain a solution.
- c) Hydroxypropyl methyl cellulose was added to the step (b) solution and stirred continuously to obtain a solution.
- d) Mifepristone was added to the step (c) solution and stirred for 5 minutes to obtain Mifepristone dispersion.
- e) Mifepristone dispersion was homogenized using IKA's Ultra TURRAX® homogenizer at 1000 RPM for 15 minutes.
- f) The above homogenized mifepristone slurry was nano-sized in ball-mill chamber to obtain nano-suspension containing desired particle size of mifepristone. The particle size distribution was measured by using Mastersizer 3000 particle analyser.
- g) Specified quantities of the silicified microcrystalline cellulose and sodium starch glycolate were dispensed in a bowl and warmed to reach 28° C. to 30° C. temperature.
- h) The nano-sized mifepristone suspension according to step (f) was sprayed onto the warmed intra-granular material according to step (g). The sprayed granules were dried at a temperature of 50° C. to 65° C. and sieved through 30 number mesh sieve.
- i) Specified quantities of milled granules of step (h), sodium starch glycolate, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate were blended and compressed using tablet compression machine. The tablets according to step (i) were coated with suitable coating materials.
Example 5
Particle Size Distribution of Mifepristone Nano-Suspensions Used in Composition G and H:
The experimental buffaloes were further divided into four groups (GnRH-0; n = 26, GnRH-100; n = 22, GnRH-150; n = 25 and GnRH-200; n = 28) according to the dose of 4th GnRH injection (0, 100, 150, and 200 μg) at day 20 of AI. The buffaloes were monitored for pregnancy losses at day 30, 40, 60, and 90 days after AI using ultrasonography. Milk samples were collected at day 20 of AI for milk P4 level (Quanzhou Ruixin Biological Technology Co., LTD) to predict the pregnancy in synchronized buffaloes. In addition, blood samples were obtained from synchronized buffaloes at days 20, 40, and 60 to observe deviation in the P4 level of buffaloes with pregnancy or embryonic loss.
We used the progesterone mimic mifepristone (RU486, Sigma-Aldrich; #M8046) to cause translocation of the flippase to the nucleus where it could then flip-out the STOP cassette in the Actin-LexAp65 transgene. We used surface application of RU486 to food vials. Parents were allowed to lay eggs in a food vial for a few days, then transferred to a fresh vial. Approximately 4 days after transfer, 60 μl of an ~10 mM RU486 stock solution (10 mg RU486 dissolved in 2 ml 95% ethanol) was applied to the surface of the food. At 24 hr after treatment, any larvae that had wandered and/or pupariated were discarded to ensure that test animals had fed on RU486 for at least 24 hr. At 48 hr after treatment, the subsequent wandering larvae and pupae (which had all fed on RU486 for 24–48 hr during the L3 stage) were collected and transferred to an untreated food vial. These animals were then dissected in Schneider’s S2 culture medium as adults. This treatment results in constitutive LexA expression in any cells that express GAL4 during the L3 stage, but, because the RU486 persists at least partway through metamorphosis, neurons that start expressing in early to mid-metamorphosis also show up.
promE-Gal4 and promE-GS-Gal4 (oeno-specific GAL4) were obtained from Dr. H. Bai(92 ). UAS-fruMA and UAS-fruCOMB were from Dr. M. Arbeitman. elav-Gal4 (BDSC#6920), UAS-fruRNAi (BDSC#31593), UAS-GFP (BDSC#5413), fru-NP21-Gal4 (BDSC# 30027), fru-P1-Gal4 (BDSC#66696), Hnf4::GFP.FLAG (BDSC#38649), UAS-Hnf4RNAi (BDSC#29375), UAS-Hnf4RNAi (BDSC#64988), UAS-dsxRNAi (BDSC#55646), Act5C-GAL4 (BDSC#4414) and W1118 (BDSC#5905) were obtained from the Bloomington Drosophila Stock Center. UAS-fru-gRNA (VDRC#342548), UAS-fruRNAi (VDRC#330035), UAS-fruRNAi (VDRC#105005) were obtained from the Vienna Drosophila Resource Center. UAS-Hnf4::HA (F000144) was obtained from FlyORF (Zurich ORFeome Project).
RU486 (mifepristone, Fisher Scientific) was dissolved in 95% ethanol, and added to standard food at a final concentration of 100 μM for all the experiments. For activation of the GeneSwitch (GS) Gal4 driver, flies were fed on RU486 food for 7 consecutive days, unless otherwise noted.
To temporally induce fru MAGIC clones, early 3rd instar larvae of w; UAS-frug-RNA/Act5C-Gal4; HS-Cas9/+ were heat shocked for 30min at 37°C, and examined at day-7 after eclosion. The HS-Cas9 stock was kindly provided by Dr. C. Han(42 (link)).
Top products related to «Mifepristone»
More about "Mifepristone"
It is widely used for the termination of early pregnancy, as well as for other medical applications such as the treatment of Cushing's syndrome.
Mifepristone works by binding to the progesterone receptor and blocking the action of the natural hormone progesterone, resulting in the disruption of early pregnancy development.
Mifepristone research is an important area of study, and researchers often utilize various related compounds and techniques to enhance their investigations.
Dexamethasone, for example, is a synthetic glucocorticoid that can be used in combination with Mifepristone to study its effects on Cushing's syndrome.
Similarly, DMSO (Dimethyl Sulfoxide) is a versatile solvent that can be used to dissolve Mifepristone for various experimental purposes.
Progesterone, the natural hormone that Mifepristone antagonizes, is another key component in Mifepristone research.
Spironolactone, a diuretic drug, can also be studied in relation to Mifepristone due to its ability to block the effects of progesterone.
Additionally, fetal bovine serum (FBS) is often used as a culture medium in Mifepristone studies, while Corticosterone, a stress hormone, can be investigated in relation to Mifepristone's effects on Cushing's syndrome.
PubCompare.ai, a leading AI-driven platform, can help optimize your Mifepristone research by providing easy access to protocols from literature, pre-prints, and patents, as well as AI-driven comparisons to identify the best protocols and products.
This can enhance the reproducibility and accuracy of your Mifepristone studies, allowing you to make more informed decisions and progress your research more effectively.